Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06386887
Other study ID # CASE1824
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 31, 2024
Est. completion date January 1, 2026

Study information

Verified date June 2024
Source Case Comprehensive Cancer Center
Contact Mariam AlHilli, MD
Phone (216) 445-8090
Email ALHILLM@ccf.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to see if timed fasting (periods of time that you don't eat) in participants who are receiving chemotherapy prior to surgery is achievable, safe and can improve quality of life, symptoms and outcomes (results) compared to participants who receive standard dietary recommendations in individuals being treated for epithelial ovarian cancer . The main questions it aims to answer are: - Is it feasible to use intermittent fasting during neoadjuvant chemotherapy? - Is it safe to use intermittent fasting during neoadjuvant chemotherapy? - Do participants find it acceptable to use intermittent fasting during neoadjuvant chemotherapy? Researchers will compare participants who receive standard dietary recommendations to see which method is more achievable, safe, and able to improve quality of life, symptoms and outcomes. Participants will: - Receive either the fasting intervention (schedule of times when you do not eat) or standard diet recommendations for 6-9 weeks prior to your surgery starting with the second cycle of chemotherapy. - All participants will be asked to complete chemotherapy and surgery, cancer imaging, baseline screening tests, nutritional assessments, food diaries, blood tests, and surveys about wellbeing. - Participants in the intervention group will be asked to follow a fasting schedule that consists of not eating for 16 hours a day followed by normal eating for the remaining 8 hours of the day for 5 days in a row followed by 2 days of regular eating each week.


Description:

The quality of diet can affect the biology of cancer. For example, evidence implies a high fat/ Western diet may impose adverse events on ovarian cancer outcomes, and the potential that the gut microbiome alterations secondary to dietary changes may impact tumor responsiveness to treatment and outcomes. This study seeks to clarify the effect of dietary intervention on the tumor and gut microbiome and ovarian cancer biology. The objectives of this study include: - Primary: To test the feasibility and safety of IF during neoadjuvant chemotherapy (including effects on body composition) - Secondary: To measure the effects of IF on participant reported outcomes, chemotherapy toxicity and quality of life. - Exploratory: To test the effect of IF on pathologic response, systemic inflammatory and immune responses, microbial diversity and metabolic pathway alterations.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date January 1, 2026
Est. primary completion date December 1, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 years and above - Participants with confirmed diagnosis of epithelial ovarian cancer (EOC) by internal cytologic or histologic evaluation (including fallopian tube and primary peritoneal cancer) - Participant who had undergone laparoscopic evaluation or laparotomy for diagnosis but did not proceed with surgical debulking - Participants with stage III or IV EOC planned to undergo NACT or already receiving NACT (cycle 1) - Any invasive ovarian cancer histology - Normal cognitive function Exclusion Criteria: - Age <18 years - Malignant complete or partial bowel obstruction confirmed on imaging. - Participants unable to provide informed consent. - BMI <18 - Participants diagnosed with severe malnutrition as assessed by study dietitian - Type I diabetes on insulin - Absence of pretreatment CT abdomen and pelvis imaging or >4-6 weeks between imaging and cycle 1 of chemotherapy.

Study Design


Intervention

Behavioral:
Intermittent Fasting
Intermittent fasting (IF) also known as time restricted eating regimen consisting of 16 hours of fasting and 8 hours of ad libitum feeding for 5 days followed by ad libitum feeding for 2 days has been proposed. With this type of intervention, there are no dietary restrictions to the type or quality of food and it decreased daily energy intake by 20%. Participants will be asked to follow an IF schedule consisting of 16 hour of continuous fasting per day for 5 days a week. This will be started 2 days prior to chemotherapy (cycle 2).
Drug:
Neoadjuvant chemotherapy
Chemotherapy will be given as standard treatment every 3 weeks (21 days) and continue for 3 to 4 cycles per routine care. As chemotherapy is not part of this research study, participants will begin standard chemotherapy as decided by their physician.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Case Comprehensive Cancer Center

Outcome

Type Measure Description Time frame Safety issue
Primary Intermittent fasting compliance as measured by serum glucose laboratory testing Participants will be assessed for intermittent fasting compliance which will be measured by metabolic laboratory tests (serum glucose) prior to each chemotherapy. Day 1 of cycle 1 (each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by ketone laboratory testing Participants will be assessed for intermittent fasting compliance which will be measured by metabolic laboratory tests (ketone) prior to each chemotherapy. Day 1 of cycle 1 (each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by IGF-1 laboratory testing Participants will be assessed for intermittent fasting compliance which will be measured by metabolic laboratory tests (IGF-1) prior to each chemotherapy. Day 1 of cycle 1 (each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by insulin laboratory testing Participants will be assessed for intermittent fasting compliance which will be measured by metabolic laboratory tests (insulin) prior to each chemotherapy. Day 1 of cycle 1 (each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by serum glucose laboratory testing Participants will be assessed for intermittent fasting compliance which will be measured by metabolic laboratory tests (serum glucose) prior to each chemotherapy. Week 3 (Day 1 of cycle 2; each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by ketone laboratory testing Participants will be assessed for intermittent fasting compliance which will be measured by metabolic laboratory tests (ketone) prior to each chemotherapy. which will be measured by metabolic laboratory tests (serum glucose, ketone, IGF-1, and insulin) prior to each chemotherapy. Week 3 (Day 1 of cycle 2; each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by IGF-1 laboratory testing Participants will be assessed for intermittent fasting compliance which will be measured by metabolic laboratory tests (IGF-1) prior to each chemotherapy. Week 3 (Day 1 of cycle 2; each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by insulin laboratory testing Participants will be assessed for intermittent fasting compliance which will be measured by metabolic laboratory tests (insulin) prior to each chemotherapy. Week 3 (Day 1 of cycle 2; each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by serum glucose laboratory testing Participants will be assessed for intermittent fasting compliance which will be measured by metabolic laboratory tests (serum glucose) prior to each chemotherapy. Week 6 (Day 1 of cycle 3; each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by ketone laboratory testing Participants will be assessed for intermittent fasting compliance which will be measured by metabolic laboratory tests (ketone) prior to each chemotherapy. Week 6 (Day 1 of cycle 3; each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by IGF-1 laboratory testing Participants will be assessed for intermittent fasting compliance which will be measured by metabolic laboratory tests (IGF-1) prior to each chemotherapy. Week 6 (Day 1 of cycle 3; each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by insulin laboratory testing Participants will be assessed for intermittent fasting compliance which will be measured by metabolic laboratory tests (insulin) prior to each chemotherapy. Week 6 (Day 1 of cycle 3; each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by self-reported assessment Participants will be assessed for intermittent fasting compliance which will be measured by a self-reported compliance checklist assessment. Week 3 (Day 1 of cycle 2; each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by self-reported assessment Participants will be assessed for intermittent fasting compliance which will be measured by a self-reported compliance checklist assessment. Week 6 (Day 1 of cycle 3; each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by food diary Participants will be assessed for intermittent fasting compliance which will be measured a 3-food diary submitted during each dietitian in person visit. Week 3 (Day 1 of cycle 2; each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by food diary Participants will be assessed for intermittent fasting compliance which will be measured a 3-food diary submitted during each dietitian in person visit. Week 6 (Day 1 of cycle 3; each cycle consisting of 21 days)
Primary Intermittent fasting compliance as measured by food diary Participants will be assessed for intermittent fasting compliance which will be measured a 3-food diary submitted during each dietitian in person visit. Up to 12 weeks post intervention
Primary Pre body composition Pre- and post- treatment body composition will be assessed by Computed Tomography scans. Baseline
Primary Post body composition Pre- and post- treatment body composition will be assessed by Computed Tomography scans. Up to 12 weeks post intervention
Secondary Chemotherapy related toxicity at Cycle 2 Participants will undergo evaluation of chemotherapy related toxicity (according to Common Terminology Criteria for Adverse Events [CTCAE version 5.0]). Week 3 (At day 1 of cycle 2; each cycle consisting of 21 days)
Secondary Chemotherapy related toxicity at Cycle 3 Participants will undergo evaluation of chemotherapy related toxicity (according to Common Terminology Criteria for Adverse Events [CTCAE version 5.0]). Week 6 (At day 1 of cycle 3; each cycle consisting of 21 days)
Secondary Chemotherapy related toxicity at Cycle 4 Participants that undergo an additional cycle of chemotherapy will undergo evaluation of chemotherapy related toxicity (according to Common Terminology Criteria for Adverse Events [CTCAE version 5.0]). Week 9 (At day 1 of cycle 4; each cycle consisting of 21 days)
Secondary Chemotherapy related toxicity at post treatment Participants will undergo evaluation of chemotherapy related toxicity (according to Common Terminology Criteria for Adverse Events [CTCAE version 5.0]), Up to 12 weeks post intervention
Secondary ESAS Score at Enrollment Participants will complete Edmonton Symptom Assessment Questionnaires (ESAS) at enrollment. The ESAS assesses pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, wellbeing, and shortness of breath. Responses are scored to produce a physical component summary and a mental component summary on a scale from 0 to 100, with higher scores indicative of better functional status. At baseline
Secondary ESAS Score at Cycle 2 Participants will complete Edmonton Symptom Assessment Questionnaires (ESAS). The ESAS assesses pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, wellbeing, and shortness of breath. Responses are scored to produce a physical component summary and a mental component summary on a scale from 0 to 100, with higher scores indicative of better functional status. Week 3 (At day 1 of cycle 2; each cycle consisting of 21 days)
Secondary ESAS Score at Cycle 3 Participants will complete Edmonton Symptom Assessment Questionnaires (ESAS). The ESAS assesses pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, wellbeing, and shortness of breath. Responses are scored to produce a physical component summary and a mental component summary on a scale from 0 to 100, with higher scores indicative of better functional status. Week 6 (At day 1 of cycle 3; each cycle consisting of 21 days)
Secondary ESAS Score at Post Treatment Participants will complete Edmonton Symptom Assessment Questionnaires (ESAS). The ESAS assesses pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, wellbeing, and shortness of breath. Responses are scored to produce a physical component summary and a mental component summary on a scale from 0 to 100, with higher scores indicative of better functional status. Up to 12 weeks post intervention
Secondary SF-125 Score at Baseline Participants will complete Study Short Form-12 Health Survey (SF-125) at enrollment. The SF-12 measures physical and mental health status. Responses are scored to produce a physical component summary and a mental component summary on a scale from 0 to 100, with higher scores indicative of better functional status. At baseline
Secondary SF-125 Score at Cycle 2 Participants will complete Study Short Form-12 Health Survey (SF-125) day 1 cycle 2. The SF-12 measures physical and mental health status. Responses are scored to produce a physical component summary and a mental component summary on a scale from 0 to 100, with higher scores indicative of better functional status. Week 3 (At day 1 of cycle 2; each cycle consisting of 21 days)
Secondary SF-125 Score at Cycle 3 Participants will complete Study Short Form-12 Health Survey (SF-125) day 1 cycle 3. The SF-12 measures physical and mental health status. Responses are scored to produce a physical component summary and a mental component summary on a scale from 0 to 100, with higher scores indicative of better functional status. Week 6 (At day 1 of cycle 3; each cycle consisting of 21 days)
Secondary SF-125 Score at Post Treatment Participants will complete Study Short Form-12 Health Survey (SF-125) post treatment. The SF-12 measures physical and mental health status. Responses are scored to produce a physical component summary and a mental component summary on a scale from 0 to 100, with higher scores indicative of better functional status. Up to 12 weeks post intervention
Secondary Pre Quality of Life (QLQ-C30) Score at Baseline Quality of life questionnaires will be distributed at enrollment and will be compared between IF and control groups. Quality of life will be measured by Quality of life will be measured with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30). EORTC QLQ-C30 is a 30 item questionnaire. Higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms. At baseline
Secondary Post Quality of Life (QLQ-C30) Score Post Treatment Quality of life questionnaires will be distributed at enrollment and will be compared between IF and control groups. Quality of life will be measured by Quality of life will be measured with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30). EORTC QLQ-C30 is a 30 item questionnaire. Higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms. Up to 12 weeks post intervention
Secondary Pre Functional Assessment (FACT-O) Score at Baseline Functional Assessment of Cancer Therapy- Ovarian (FACT-O) will be administered post treatment and will be compared between IF and control groups. FACT-O is a 39 item questionnaire with a 5 point Likert-type scale. Scores range from 0-156. The higher the score, the better the quality of life. Up to 12 weeks post intervention
Secondary Post Functional Assessment (FACT-O) Score Post Treatment Functional Assessment of Cancer Therapy- Ovarian (FACT-O) will be administered at enrollment and will be compared between IF and control groups. FACT-O is a 39 item questionnaire with a 5 point Likert-type scale. Scores range from 0-156. The higher the score, the better the quality of life. Up to 12 weeks post intervention
Secondary AIM Survey Score at Cycle 2 Acceptability of intervention Measure (AIM) questionnaire will be administered IF participants. AIM has 4 item psychometric assessment times measuring acceptability of intervention. Scale values range from 1 to 5. Overall scores that are lower indicating lower acceptability, and higher scores indicating greater acceptability, appropriateness, and feasibility. Week 3 (At day 1 of cycle 2; each cycle consisting of 21 days)
Secondary AIM Survey Score at Cycle 3 Acceptability of intervention Measure (AIM) questionnaire will be administered IF participants. AIM has 4 item psychometric assessment times measuring acceptability of intervention. Scale values range from 1 to 5. Overall scores that are lower indicating lower acceptability, and higher scores indicating greater acceptability, appropriateness, and feasibility. Week 6 (At day 1 of cycle 3; each cycle consisting of 21 days)
Secondary AIM Survey Score at Post Treatment Acceptability of intervention Measure (AIM) questionnaire will be administered IF participants. AIM has 4 item psychometric assessment times measuring acceptability of intervention. Scale values range from 1 to 5. Overall scores that are lower indicating lower acceptability, and higher scores indicating greater acceptability, appropriateness, and feasibility. Up to 12 weeks post intervention
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03393884 - Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) Phase 1/Phase 2
Recruiting NCT05200559 - T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT04546373 - Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Completed NCT01442051 - Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer N/A
Not yet recruiting NCT04983550 - Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC Phase 2
Completed NCT02480374 - Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer Phase 1
Recruiting NCT01680575 - Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer N/A
Terminated NCT01202890 - Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer Phase 1
Completed NCT00561795 - Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors Phase 2
Completed NCT00314678 - Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer Phase 2
Not yet recruiting NCT04889495 - A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Not yet recruiting NCT06010667 - A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
Recruiting NCT06085456 - Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective Study
Completed NCT06366997 - Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) Test
Active, not recruiting NCT05212779 - Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
Recruiting NCT04620954 - Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin Phase 1/Phase 2
Completed NCT02312661 - Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer Phase 1
Completed NCT01666444 - VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Phase 2
Completed NCT01891344 - A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Phase 2